IT Type
Antibody-based IT
Description
35-scFv-ETA immunotoxin directs at fetal AchR, wherein the immunotoxin comprises a human scFv fragment based on a human autoantibody 35 and a pseudomonas exotoxin A. 35-scFv-ETA is the first cancer-directed immunotoxin with a fully human antibody moiety and the first IT targeting an antigen that is virtually specific for RMS. 35-scFv-ETA appears promising for further preclinical evaluation as a therapeutic tool against high-risk RMS.
Indication
Lung cancer
Classification
Immuntoxin; biobetter
Construction
35(scFv)-ETA
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
AChR
Full Name
AChR
Background
An acetylcholine receptor (abbreviated AChR) is an integral membrane protein that responds to the binding of acetylcholine, a neurotransmitter.
Alternative Names
AChR
Antibody Clone
35
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
Fab
Antibody Indication
Lung cancer
Toxic Moiety
Exfoliative toxin A (ETA)
Organism
Staphylococcus aureus
Family
Exfoliative toxin
Toxic MOA
The exfoliative toxins (ETs) also known as epidermolytic toxins, are serine proteases secreted by S. aureus that recognize and hydrolyze desmosome proteins. S. aureus ETs are serine proteases, which exhibit exquisite substrate specificity, and their mechanisms of action are extremely complex. However, the exact molecular mechanisms of ET‐causing epidermal blisters had long been unknown over the three decades.
The antibody portion mediated selective binding to target cells, while the toxin portion mediated translocation into the cytosol and subsequent cell killing.
